Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer

Business Wire November 4, 2015

ViiV Healthcare Announces Positive Headline Results from a Study of Two Drug Injectable Regimen for HIV Maintenance Therapy

PR Newswire November 3, 2015

New Data Continue to Characterize the Safety and Efficacy of XELJANZ® (tofacitinib citrate) in the Treatment of Rheumatoid Arthritis

Business Wire November 2, 2015

ETF Week Ahead Preview: Hoping For No November Rain

Benzinga.com  November 2, 2015

Pfizer Inc. Announcement under Rule 2.10 of the Irish Takeover Rules - Relevant Securities in Issue

Business Wire October 30, 2015

Pfizer Announcement Regarding Allergan plc

Business Wire October 29, 2015

Pfizer Announces Collaboration with GSK on Next-Generation Design of Portable, Continuous, Miniature and Modular (PCMM) Oral Solid Dose Development and Manufacturing Units

Business Wire October 29, 2015

These ETFs Should Love The Pfizer-Allergan News

Benzinga.com  October 29, 2015

PFIZER REPORTS THIRD-QUARTER 2015 RESULTS

Business Wire October 27, 2015

ViiV Healthcare Awards 23 Small Grants to Help Alleviate the Stigma of HIV and AIDS in the MSM and Transgender Community Globally

PR Newswire October 26, 2015

Pfizer's Inotuzumab Ozogamicin Receives FDA Breakthrough Therapy Designation for Acute Lymphoblastic Leukemia (ALL)

Business Wire October 19, 2015

Pfizer Receives Complete Response Letter from FDA for Oral XELJANZ® (tofacitinib citrate) Supplemental New Drug Application for Moderate to Severe Chronic Plaque Psoriasis

Business Wire October 14, 2015

Biotech ETFs Get More Refined With Debut Of Cancer Immunotherapy Fund

Benzinga.com  October 14, 2015

Pfizer and the Union for International Cancer Control Award 20 Grants Totaling $760,000 to Address the Needs of Metastatic Breast Cancer Patients Worldwide

Business Wire October 13, 2015

Pfizer's Phase 2 Study Demonstrates Safety, Tolerability and Immunogenicity of TRUMENBA® When Coadministered with Meningococcal A, C, Y and W-135 Polysaccharide Conjugate (MCV4) and Tetanus, Diphtheria and Pertussis (Tdap) Vaccines in Adolescents

Business Wire October 9, 2015

Merck KGaA, Darmstadt, Germany, and Pfizer Announce Investigational Immunotherapy Avelumab Receives FDA Fast Track Designation for Metastatic Merkel Cell Carcinoma

Business Wire October 7, 2015

Pfizer Inc. Announces Final Results of Exchange Offers

Business Wire October 2, 2015

Pfizer Completes Acquisition Of Nimenrix And Mencevax From GlaxoSmithKline

Business Wire October 1, 2015

Pfizer Partners with Breast Cancer Leaders to Chronicle the Lives of Women with Metastatic Breast Cancer through the Lenses of Prominent Photographers

Business Wire September 30, 2015

Pfizer Updates 2015 Financial Guidance Solely to Include Hospira Operations In Financial Results From September 3, 2015 Through Year-End 2015

Business Wire September 30, 2015